Extracorporeal life support during cardiac arrest and cardiogenic shock—how good is the evidence really?

Roland Prondzinsky¹, Karl Werdan²

¹Department of Medicine I, Carl-von-Basedow Hospital Merseburg, Merseburg, Germany; ²Department of Medicine III, University Hospital Halle (Saale) of the Martin-Luther University Halle-Wittenberg, Halle (Saale), Germany

Correspondence to: Prof. Dr. med. Karl Werdan. Department of Internal Medicine III, University Hospital Halle (Saale), Ernst-Grube Str. 40, D-06120 Halle (Saale), Germany. Email: karl.werdan@medizin.uni-halle.de. 

Provenance: This is a Guest Commentary commissioned by Section Editor Zhi Mao, MD (Department of Critical Care Medicine, Chinese People's Liberation Army General Hospital, Beijing, China).


Submitted Nov 05, 2016. Accepted for publication Nov 27, 2016. doi: 10.21037/atm.2017.01.30

View this article at: http://dx.doi.org/10.21037/atm.2017.01.30

For emergency physicians and cardiologists, patients with refractory cardiac arrest or cardiogenic shock complicating myocardial infarction are children of sorrow: mortality is extremely high, and not much improvement can be reported for the last decades. At least the beneficial effect of early revascularization was clarified by the SHOCK-Trial (1), with an estimated risk reduction (30-days/1-year-mortality) amounting to about 18% [relative risk (RR) 0.82 (95% CI 0.69–0.97)] by primary percutaneous intervention/primary coronary artery bypass grafting (2). Nevertheless mortality still remains high. No wonder that not only drugs but also mechanical support devices like the intraaortic balloon pump (IABP) or pumps like the Impella or the TandemHeart are in the therapeutic scope, to increase cardiac output and thereby transiently stabilize haemodynamics (2,3). With the use of extracorporeal life support (ECLS)/veno-arterial extracorporeal membrane oxygenation (VA-ECMO), not only cardiac function can be supported, but also pulmonary function. All these devices have been used for a long time despite a lack of evidence from randomized controlled trials (RCTs), only based on recommendations by experts and our confidence in pathophysiology, reckoning that an increase in cardiac output should improve survival.

However, after presentation of the IABP-SHOCK II trial in 2012/2013 (4,5) with neutral results of IABP in patients with myocardial infarction complicated by cardiogenic shock, IABP use in Germany dropped nearly by half, from about 8,500 in 2012 to about 5,000 in 2014 (6). Vice versa, the application numbers for other percutaneous mechanical support devices increased, for instance, for VA-ECMO in Germany from about 500 in 2012 to about 3,000 in 2014 (6).

This dramatic increase, however, is alarming, because all these instrumentations are not based on firm evidence, but rather on “pathophysiology-driven common sense”. An increase in cardiac output and oxygenation by ECLS in refractory cardiac arrest and cardiogenic shock is mandatory, but does not guarantee an improved survival of these patients.

In view of this uncertainty due to the lack of RCTs, we really welcome the systematic review and meta-analysis of extracardiac life support during cardiac arrest and cardiogenic shock complicating myocardial infarction by Ouweneel et al. (7). This publication comes from the group of Professor Josef P.S. Henriques from Amsterdam, highly renowned in this field. The authors systematically searched MEDLINE, EMBASE, the Cochrane Central Register of Controlled Trials and the published subset of PubMed updated to December 2015. Nine of the 13 studies—all cohort studies and no RCTs at all—reported about cardiac arrest patients (n=3,098) and four included patients with cardiogenic shock after acute myocardial infarction (n=235). Analysis included data pooling by a Mantel-Haenzel random effects model, and heterogeneity was examined by
Table 1 Effect of ECLS in patients with refractory cardiac arrest and in patients with cardiogenic shock complicating myocardial infarction. Summary of main results from the recent meta-analysis of Ouweneel et al. (7)

<table>
<thead>
<tr>
<th>Patient group</th>
<th>Endpoint</th>
<th>Studies (n)</th>
<th>Patients (n)</th>
<th>Absolute risk difference (95% CI) ECLS vs. control</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cardiac arrest</td>
<td>30-day survival</td>
<td>8</td>
<td>2,774</td>
<td>0.13 (0.06 vs. 0.20)</td>
<td>0.0002</td>
</tr>
<tr>
<td></td>
<td>30-day favourable neurological outcome</td>
<td>5</td>
<td>1,590</td>
<td>0.14 (0.07 vs. 0.20)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Cardiogenic shock</td>
<td>ECLS vs. IABP</td>
<td>30-day survival</td>
<td>2</td>
<td>95</td>
<td>0.33 (0.14 vs. 0.52)</td>
</tr>
<tr>
<td></td>
<td>ECLS vs. Impella/TandemHeart</td>
<td>30-day survival</td>
<td>2</td>
<td>140</td>
<td>−0.03 (−0.21 vs. 0.14)</td>
</tr>
<tr>
<td></td>
<td>ECLS vs. IABP/Impella/TandemHeart</td>
<td>30-day survival</td>
<td>4</td>
<td>235</td>
<td>0.14 (−0.08 vs. 0.35)</td>
</tr>
</tbody>
</table>

ECLS, extracorporeal life support; IABP, intraaortic balloon pump; Impella, Impella®, a percutaneous ventricular assist device; TandemHeart, TandemHeart®, a percutaneous ventricular assist device.

the I² statistic. In refractory cardiac arrest (Table 1), the use of ECLS was associated with an absolute increase of 30-day survival of 13% compared with patients in whom ECLS was not used [95% CI: 6–20%; P<0.001; numbers needed to treat (NNT): 7.7], and it was also associated with a higher rate of favourable neurological outcome at 30 days (absolute risk difference 14%; 95% CI: 7–20%; P=0.0001; NNT: 7.1). Similar results showed propensity matched analysis, including five studies and 438 patients (219 in both groups). In cardiogenic shock (Table 1), ECLS showed a 33% higher 30-day survival compared with IABP (absolute risk difference 0.33; 95% CI: 0.14–0.52; P<0.001; NNT: 3), but no difference when compared with Impella/TandemHeart (−0.03; 95% CI: −0.21 to 0.14; P=0.70; NNH: 33) and also no significant difference to the pooled data (0.14; 95% CI: −0.08 to 0.35; P=0.20; NNT: 7.1). Only two studies reported complications, amounting to about 15% with regards to peripheral vessels complications/leg ischaemia, including 3% of compartment syndromes. From their findings the authors concluded that (I) in cardiac arrest, the use of ECLS was associated with an increased survival rate as well as an increase in favourable neurological outcome and (II) in the setting of cardiogenic shock there was an increased survival with ECLS compared with IABP.

We can accept these conclusions in case of cardiac arrest patients, but in case of patients with cardiogenic shock complicating myocardial infarction, we have to solve a problem: we can agree that ECLS is better than IABP, as we know that IABP does not lower 30-day mortality in these patients (4). On the other hand, the authors also showed that ECLS is not better than device treatment with Impella/TandemHeart (Table 1). However, nobody yet has shown that treatment with Impella/TandemHeart improves prognosis in patients with cardiogenic shock complicating myocardial infarction. So, when treatment with Impella/TandemHeart is not proven and treatment with ECLS is not better than Impella/TandemHeart use, we still do not know—as the authors state—whether ECLS treatment indeed improves survival in those patients.

Can we “trust” the positive results of the presented meta-analysis? For us, the results of this meta-analysis with respect to refractory cardiac arrest are more convincing than those for cardiogenic shock. They further support the resuscitation guidelines (8,9), which give a “weak recommendation with very-low-quality evidence” and suggest that “ECPR” (extracorporeal cardiopulmonary resuscitation) “is a reasonable rescue therapy for selected patients with cardiac arrest when initial conventional CPR is failing in settings where this can be implemented” (8).

In principle, a word of scepticism is always indicated whenever results of meta-analyses are solely based on non-randomized trials. And this, indeed, is especially the case concerning the results propagated for patients with cardiogenic shock complicating myocardial infarction, as all these studies are cohort studies moreover with only small numbers of patients (Tables 1, 2).

ECLS may be beneficial for patients with CS, but for which patient at which point of time? To answer these questions not only hemodynamic instability has to be taken into account, but also the degree of systemic inflammation (SIRS) and consecutive established microcirculatory disturbances. A clinical approximation to this question might be the early calculation of appropriate scores to estimate the severity of multi-organ dysfunction or even failure. We could demonstrate the prognostic value of the APACHE II score in patients with infarct related
cardiogenic shock (10). And we are convinced that there will be patients who will benefit from the means of ECLS, but we are in need for valid instruments to identify these patients. The answers to the questions given above could also help to choose the best of the available devices for the individual patient.

So, can we really “trust” the work presented by Henriques-team? We think, we can! In 2009, the Henriques team published a systematic review and meta-analysis of the role of IABP in STEMI patients (11) (Table 2). And based on their neutral findings, the authors provocatively asked in their title: “Should we change the guidelines?” At that time, the use of IABP in STEMI patients with cardiogenic shock was a class I recommendation in the guidelines. We, at that time, did the IABP SHOCK trial (10), a small randomized trial with 40 STEMI patients with cardiogenic shock complicating myocardial infarction. We could not see any improvement in the severity of disease—as measured by the APACHE II score—from day 0 to day 4. IABP, intraaortic balloon pump; ECLS, extracorporeal life support; PCI, percutaneous coronary intervention; RCT, randomized controlled trial; APACHE, Acute Physiology And Chronic Health Evaluation; IQR, interquartile range; RR, relative risk; HR, hazard ratio; NNT, numbers needed to treat.

Table 2 Effects of IABP and of ECLS in patients with cardiogenic shock complicating myocardial infarction treated by primary PCI—study results

<table>
<thead>
<tr>
<th>Device</th>
<th>RCT</th>
<th>Meta-analyses</th>
<th>Non-randomized trials</th>
</tr>
</thead>
<tbody>
<tr>
<td>IABP</td>
<td>IABP-SHOCK trial (10); n=40; ∆ APACHE II score over 4 days (IABP vs. no IABP); ∆ −2.8 vs. ∆ −2.2 (n.s.)</td>
<td>Sjauw 2009 (11); n=3,282; 30-day mortality (IABP vs. no IABP): 47.0% vs. 40.7%; risk difference: 0.06 (IQR 0.03 to 0.10); P&lt;0.0008</td>
<td>–</td>
</tr>
<tr>
<td></td>
<td>IABP-SHOCK II trial (4); n=600; 30-day mortality (IABP vs. no IABP): 39.7% vs. 41.3%; RR: 0.96 (IQR 0.79 to 1.17); P=0.69</td>
<td>Unverzagt 2015 (12); n=662; 30-day mortality (IABP vs. no IABP): HR 0.94 (IQR 0.74 vs. 1.20)</td>
<td>–</td>
</tr>
<tr>
<td>ECLS</td>
<td>–</td>
<td>Ouweneel 2016 (7); n=95; 30-day survival (ECLS vs. IABP): 62.1% vs. 29.7%; absolute risk difference: 33% (IQR 14% to 52%); P=0.008; NNT 13</td>
<td>Sheu 2010 (13); prospective recruitment, historical controls; n=71 (profound cardiogenic shock); 30-day mortality (ECLS vs. no ECLS): 39.1% vs. 72%, P=0.008</td>
</tr>
<tr>
<td></td>
<td>–</td>
<td>Sattler 2014 (14); post hoc analysis; n=24; 30-day mortality (ECLS vs. no ECLS): 33% vs. 67%</td>
<td>–</td>
</tr>
</tbody>
</table>

*, primary endpoint is the change of the APACHE II score from day 0 to day 4. IABP, intraaortic balloon pump; ECLS, extracorporeal life support; PCI, percutaneous coronary intervention; RCT, randomized controlled trial; APACHE, Acute Physiology And Chronic Health Evaluation; IQR, interquartile range; RR, relative risk; HR, hazard ratio; NNT, numbers needed to treat.

The recent meta-analysis of the Henriques-team (7) about ECLS during cardiac arrest and cardiogenic shock has not a neutral result as in case of the IABP-meta-analysis (11), but a positive one. But does this mean that we now should routinely apply ECSL in refractory cardiac arrest and in cardiogenic shock? The answer is clearly “no”, as even a good meta-analysis as those reported by Ouweneel et al. (7) is not enough for recommendation requiring a RCT with an endpoint “survival”. And a prospective, randomized, controlled ECLS trial in patients with refractory cardiac arrest as well as in patients with cardiogenic shock complicating myocardial infarction could indeed be done: the IABP-SHOCK II trial with 600 patients—exclusively included in a single country (Germany) —was the proof of principle!

Following the line of the IABP-SHOCK trial and the IABP-SHOCK II trial: we eagerly await an “ECLS-ARREST” trial and an “ECLS-SHOCK” trial!

Acknowledgements

The authors gratefully acknowledge stimulating discussions with members (S Nuding, J Schröder, T Otto and L Thieme) of the TEMPHUS project team FKZ: I3GW0034B. The TEMPHUS project (FKZ: I3GW0034B) about temporary mechanical support is sponsored by the German Ministry of...
Footnote

Conflicts of Interest: K Werdan, formerly Director of the Department of Medicine III of the University Hospital Halle (Saale) Germany, is now working in the Department of Medicine III as scientist of the TEMPHUS project team (FKZ: 13GW0034B) about temporary mechanical support, sponsored by the German Ministry of Education and Research (BMBF). R Prondzinsky has no conflicts of interest to declare.

References


Cite this article as: Prondzinsky R, Werdan K. Extracorporeal life support during cardiac arrest and cardiogenic shock—how good is the evidence really? Ann Transl Med 2017;5(3):58. doi: 10.21037/atm.2017.01.30